Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing bone marrow cells, a common complication known as chemotherapy-induced thrombocytopenia. Romiplostim boosts the bone marrow’s ability to withstand the assault of chemotherapy so that recipients of the medication can continue to make platelets that are needed to prevent bleeding.
This article was originally published on MedicalXpress.com
